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Abstract
Introduction: The role of CD3−CD56+ natural killer (NK) cells in granulomatosis with polyangiitis (GPA) is poorly
understood. Recently, it has been shown that peripheral blood NK cells can kill renal microvascular endothelial cells,
suggesting a pathogenic role of NK cells in this disease. So far, subset distribution, phenotype, and function of
peripheral blood NK cells in relation to GPA disease activity have not been elucidated. Moreover, it is not known
whether NK cells infiltrate GPA tissue lesions.
Methods: Paraffin sections of GPA granulomas and controls were stained with anti-CD56 and anti-CD3 antibodies.
Peripheral blood lymphocyte subsets were analyzed by flow cytometry. NK cell degranulation was analyzed using
cocultures of patient PBMCs with target cells and surface expression of CD107a. Clinical data were extracted from
medical records. Statistical analysis was performed in an exploratory way.
Results: CD56+ cells were not detectable in active granulomatous GPA lesions but were found frequently in granulomas
from tuberculosis and sarcoidosis patients. In GPA, the proportion of NK cells among peripheral blood lymphocytes
correlated negatively with the Birmingham Vasculitis Activity Score (BVAS) (n = 28). Accordingly, NK cell percentages
correlated positively with the duration of remission (n = 28) and were significantly higher in inactive GPA
(BVAS = 0, n = 17) than in active GPA, healthy controls (n = 29), and inactive control diseases (n = 12). The
highest NK cell percentages were found in patients with long-term remission and tapered immunosuppressive
therapy. NK cell percentages >18.5 % of peripheral blood lymphocytes (n = 12/28) determined GPA inactivity
with a specificity of 100 %. The differentiation into CD56dim and CD56bright NK cell subsets was unchanged in
GPA (n = 28), irrespective of disease activity. Similar surface expression of the activating NK cell-receptors
(NKp30, NKp46, and NKG2D) was determined. Like in healthy controls, GPA NK cells degranulated in the
presence of NK cell receptor ligand bearing epithelial and lymphatic target cells.
Conclusions: NK cells were not detectable in GPA granulomas. Peripheral blood NK cell percentages
positively correlate with the suppression of GPA activity and could serve as a biomarker for GPA activity.
Peripheral blood NK cells in GPA patients are mature NK cells with preserved immune recognition.
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Introduction
Granulomatosis with polyangiitis (GPA) is a systemic in-
flammatory disease. European League Against Rheuma-
tism (EULAR) treatment recommendations published in
2009 [1] propose an induction therapy consisting of
cyclophosphamide and high-dose steroids followed by a
maintenance therapy with disease-modifying antirheu-
matic drugs (DMARDs) and low-dose steroids. Recent
studies showed high efficacy of the anti-CD20 anti-
body rituximab in induction [2–4] and maintenance
therapies [5, 6]. To date, it is unclear how long main-
tenance therapy should be continued.
The Birmingham Vasculitis Activity Score (BVAS) is a
standard activity score used in studies of GPA. The pres-
ence of anti-proteinase 3 antibodies (PR3) is specific for
GPA. However, consideration of PR3 serum levels as an
activity marker has been discussed controversially [7]. So
far, no laboratory test can reliably be used as an activity
biomarker [8].
Granulomas and vasculitis define GPA histologically.
GPA granulomas consist of granulocytes surrounded by
T and B cells [9, 10]. Granulocytes express the key anti-
gen proteinase 3. So far, mainly granulocytes, macro-
phages, fibroblasts, T cells, and B cells have been studied
in GPA [10–15]. Knowledge about an implication of nat-
ural killer (NK) cells in GPA is very limited. Tognarelli
et al. [16] recently reported that NK cells from patients
with GPA can directly kill renal microvascular endothe-
lial cells (MECs) ex vivo. They concluded that NK cells
may participate in vasculitis of the kidney. However, they
studied NK cell frequency, subset distribution, pheno-
type, and function of peripheral blood NK cells in rela-
tively few patients and not in relation to GPA disease
activity. Importantly, whether NK cells can be found in
GPA tissue lesions is currently unknown.
Among peripheral blood lymphocytes (PBLs), NK cells
make up a considerable proportion (5–15 %). They pro-
vide a first-line defense against intracellular pathogens
and tumors [17, 18]. Two major subsets are well estab-
lished: CD56bright NK cells are dominant in secondary
lymphatic tissues and presumably parental cells of
CD56dim NK cells. CD56dim NK cells are mature and
more cytotoxic cells and make up >90 % of peripheral
blood NK cells. NK cell effector mechanisms are cyto-
toxicity and secretion of inflammatory cytokines and
chemokines. The surface expression of the NK cell de-
granulation marker CD107a is strongly associated with
NK cell cytotoxicity [19]. NK cell immune recognition
and activity are balanced by activating and inhibiting re-
ceptors [20], but they can be modulated on several levels
[21]. NK cells are regarded as a link between innate and
adaptive immunity [22]. Importantly, adaptive immunity
can be modulated by NK cells at different stages [23],
such as by secretion of interleukin (IL)-10 [24] and
killing of other immune cells, including activated CD4+
T cells and B cells [25–27].
Material and methods
Patient consent and ethical approval
Informed consent was obtained from the patients before
study initiation. The ethics committee of the University
of Heidelberg approved this study.
Histology
Paraffin-embedded sections from 13 GPA granulomas
(12 in lungs, 1 in kidney) of 10 different patients with
GPA and each 5 granulomas from patients with tubercu-
losis and sarcoidosis were processed. The following
primary antibodies were used: rabbit anti-human
monoclonal antibody (mAb) CD3 (clone SP7, immuno-
globulin G (IgG), 1:200; Thermo Fisher Scientific, Fre-
mont, CA, USA) and mouse anti-human CD56 mAb
(clone 1B6, IgG1, 1:10; Leica Biosystems, Newcastle
upon Tyne, UK). Isotype- and concentration-matched
mouse and rabbit control mAb (Dianova, Hamburg,
Germany) served as negative controls. Immunoenzyme
staining was performed on 2-μm paraffin-embedded sec-
tions of formalin-fixed tissue using automated staining with
the DAKO autostainer according to the manufacturer’s in-
structions (Dako, Glostrup, Denmark). Antigen retrieval for
CD3 was achieved by steam-cooking the slides in 1 mM
ethylenediaminetetraacetic acid buffer (pH 9; Dako) and for
CD56 in 10 mM citrate buffer (pH 6.1; Dako) for 30 minutes.
3,3′-Diaminobenzidine was used as the substrate.
Patients and controls
Heparinized blood was drawn from 30 patients with
GPA. One patient was excluded because of concomitant
B-cell malignancy, and another one was excluded be-
cause the diagnosis of GPA could not be retraced suffi-
ciently. The 28 analyzed patients (Table 1) did not have
significant comorbidities. Of note, in three patients with
NK cell frequencies over 40 %, no common pathology
apart from GPA was found in the available patient re-
cords. One female patient with 57.4 % NK cells had been
in remission for almost 5 years and had received trastu-
zumab (HER2 antibody) for treatment of breast cancer.
It cannot be excluded that trastuzumab was in part re-
sponsible for this high NK cell proportion. Exclusion of
this patient from the analysis did not relevantly alter the
statistical significance data presented in this study.
A total of 29 volunteers (15 men, 14 women; median
age 49.5 years) without systemic inflammatory diseases
or other active illness served as healthy controls (HCs).
Twelve patients with inactive systemic inflammatory dis-
eases other than GPA represented a group constituting
inactive control diseases (CDs): systemic lupus erythe-
matosus (n = 4), panarteritis nodosa (n = 1), overlap
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connective tissue disease (n = 1), chronic inflammatory
bowel disease (n = 1), CREST (calcinosis, Raynaud’s
phenomenon, esophageal dysmotility, sclerodactyly, and
telangiectasia) syndrome (n = 1), primary Sjögren’s syn-
drome (n = 1), polymyalgia rheumatica (n = 1), and giant
cell arteritis (n = 2).
Definitions and analysis of medical records
BVAS was determined at the time of blood donation
(i.e., the day of inclusion in the study). Inactive and ac-
tive GPA were defined by BVASs of 0 and ≥1, respect-
ively. As BVAS was not determined in routine clinical
practice, the following terminology was used to retro-
spectively analyze disease courses. Relapses were defined
by major disease activity necessarily resulting in reinduc-
tion therapy. Disease activity included initial disease
flares and relapses as well as every situation with GPA
activity that did not result in (re-)induction therapy but
met at least one of the following criteria: (1) new or aug-
mented organ involvement, (2) entry activity or relapse
in medical report, and (3) increased immunosuppressive
therapy. Duration of remission was defined by the length
of time since last disease activity.
Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were
isolated using Ficoll-Paque density gradient medium
(GE Healthcare Life Sciences, Uppsala, Sweden) and
incubated for 30 minutes on ice with a mixture of
antibodies (fluorescein isothiocyanate anti-CD3;
phycoerythrin/Cy7 anti-CD56 in every experiment;
and additionally in some experiments, allophycocyanin
anti-CD19; all from BioLegend, San Diego, CA, USA)
and 7-aminoactinomycin D (7-AAD; BD Biosciences,
San Jose, CA, USA). After being washed, PBMCs
were resuspended in a fixation solution and immedi-
ately analyzed by flow cytometry. Lymphocyte subsets
from 9 of the 14 CD patients were analyzed accord-
ing to our clinical laboratory routine using a standard
antibody kit from Beckman Coulter (Brea, CA, USA).
Degranulation (CD107a) assays
PBMCs were isolated as described, frozen the same day,
thawed the day before the experiment, and cultured
overnight. PBMCs (105) were cocultured for 4 h (37 °C,
5 % CO2) with target cells in a 1:1 ratio. Cocultures were
performed in duplicates in 200 μl of RPMI per well on a
96-well plate. Anti-CD107a mAb (BioLegend) was added
at the beginning of the coculture in combination with
0.25 μl of Golgi-Stop (BD Biosciences). After two wash-
ing steps, PBMCs and target cells were incubated with
antibodies for cell surface staining and analyzed by flow
cytometry as described above. Additive effect on de-
granulation is defined by the percentage of NK cells
expressing the degranulation marker CD107a after incu-
bation with target cells minus the percentage of NK cells
expressing the degranulation marker CD107a after incu-
bation without target cells.
As target cells, major histocompatibility complex
class I–positive BxPC-3 (pancreatic carcinoma) cells
and JE6-1 (leukemic Jurkat) cells were used [retrovi-
rally transfected with pMXneo (vector control, VC)
and pMXneo-CD8L-Myc tag-B7-H6, respectively, and
cultured as previously described] [28]. B7-H6 expression
was controlled using an anti-B7-H6 antibody [28].
Statistical analysis
The statistical analysis was performed in an exploratory
way. The p values have to be interpreted descriptively. A
normal distribution of NK cell percentages and counts
was not assumed; therefore, non-parametric statistical
tests were used. The Kruskal-Wallis test and Dunn’s
posttest were used for multiple comparisons. The
Mann-Whitney U test was used to compare two patient
Table 1 Patient characteristics
Characteristics Data
Patients with GPA, n 28
Male/female, n 16/12
Age, yr, mean ± SD (range) 61.8 ± 16.6 (30–81)
Patients with active GPA (BVAS >0), n (%) 11/28 (39 %)
BVAS (of active GPA), mean ± SD 6.8 ± 7.5
Patients with inactive GPA (BVAS = 0), n (%) 17/28 (61 %)
Duration of remission, yr (of inactive GPA),
median ± SD
4.08 ± 2.3
Organ system involvement, n (%)
ENT 23/28 (82 %)
Lung 15/28 (54 %)
Kidney 18/28 (64 %)
Skin 8/28 (29 %)
Joints 12/28 (43 %)
NS 8/28 (29 %)
Localized GPA (upper airways and ENT
organs only), n (%)
3/28 (11 %)
Generalized GPA, n (%) 25/28 (89 %)
Number of involved organ systems, mean ± SD 4.3 ± 1.2
Number of relapses, mean ± SD (range) 1.1 ± 1.4 (0–5)
Length of time since disease onset, yr, mean ± SD 9.4 ± 7.9
c-ANCA, n (%)
Positive 22/28 (79 %)
Negative 3/28 (11 %)
Not determinable 3/28 (11 %)
c-ANCA cytoplasmic antineutrophil cytoplasmic antibodies, GPA granulomatosis
with polyangiitis, ENT ear, nose, and throat, NS nervous system, PR3 anti-proteinase
3 antibody, SD standard deviation
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groups. Spearman’s test was used to investigate correla-
tions. Receiver operating characteristic (ROC) curves
were created to investigate the usefulness of parameters
as a test to distinguish between two groups. On the basis
of ROC curves, suitable threshold values delivering the
best test performance were determined. A paired t test
was used to compare NK cells of the same donor after
coculture with differently transfected target cells. All
tests were performed with a significance level of 5 %
(confidence interval 95 %).
Results
CD56+ cells were not detectable in GPA but were present
in granulomas of classical granulomatous diseases
Thirteen histological sections of GPA granulomas were
stained for CD3 and CD56 (Fig. 1a). All GPA granu-
lomas were completely negative for CD56 staining.
However, scattered CD56+ cells were found in normal
lung tissue at section borders (not shown). The non-
detectable levels of CD56 were specific for GPA, as
abundant CD56+ cells were found in each of five tuber-
culosis and sarcoidosis granulomas (Fig. 1a). Presumably,
at least a few CD56+ cells in tuberculosis and sarcoidosis
granulomas represented NK cells because, despite the
difficult identification of CD3-CD56+ cells in sequen-
tial sections due to massive CD3+ infiltrates, some
CD3-CD56+ cells could be identified (Fig. 1b).
NK cell percentages in PBLs negatively correlate with GPA
activity and are increased in inactive GPA
NK cells of patients and HCs were defined as living
(7-AAD–negative) CD3−CD56+ cells (Fig. 2a) and
showed comparable expression of the NK-specific
marker NK cell p46-related protein (NKp46; not
shown). In addition, CD3−CD56+ cells were consist-
ently CD19− (not shown).
A correlation study was performed after pooling of
all patients (n = 28) independently of disease activity.
NK cell proportions correlated negatively with BVAS
(r = −0.65, p = 0.0002) (Fig. 2b). In a subset of pa-
tients, absolute lymphocyte counts were determined
for diagnostic purposes, which enabled us to calculate
absolute NK cell counts. Absolute NK cell counts
confirmed the negative correlation with BVAS (n = 11,
r = −0.79, p = 0.0047) (not shown).
Patients with inactive GPA (n = 17) had significantly
greater NK cell proportions in PBLs than did patients
with active GPA (n = 11) and HCs (n = 29) (Fig. 2c, left
graph). This increase was not a generalizable feature of
immune disease in remission, as shown by comparison
with inactive CD (n = 12) (Fig. 2c). Similar to NK cell
proportions, absolute NK cell counts were significantly
increased in inactive GPA (n = 5) compared with active
GPA (n = 6) and inactive CD (n = 12) (Fig. 2c, right
graph).
As HCs were slightly younger than patients with GPA
(Table 1), we examined a possible influence of age on
NK cell proportions. Patients with active GPA and pa-
tients with inactive GPA patients differed slightly in
mean age (mean age 54 and 65 years, respectively).
However, there was no statistically significant correlation
between age and NK cell proportions in patients with
GPA (Spearman’s r = 0.26, p = 0,187; not shown).
To exclude increased expression of CD56 on cell types
that are not NK cells, we also determined CD56+ T-cell
proportions. CD56+ T-cell proportions were similar in ac-
tive (n = 11) and inactive (n = 17) GPA, as well as in HCs
(n = 29) (Fig. 2d). CD56− but not CD56+ T-cell propor-
tions were significantly different (p = 0.04 by Kruskal-
Wallis test). Compared with HCs, patients with inactive
GPA showed statistically significantly lesser CD56− T-cell
proportions (Fig. 2d).
Next, we evaluated the power of NK cell proportions
to determine GPA inactivity. A ROC curve was created
(Fig. 2e) showing the sensitivity and specificity of differ-
ent NK cell proportions to distinguish inactive from ac-
tive GPA. NK cells >18.5 % of PBLs determined
inactivity with a specificity of 100 % and a sensitivity of
71 %, resulting in a positive likelihood ratio >72. NK
cells >18.5 % of PBLs were detected in 12 of 28 patients.
The area under the curve was 0.9.
Together, these data demonstrate that NK cell propor-
tions negatively correlated with GPA activity and were
significantly increased in inactive GPA. A positive likeli-
hood ratio >8 indicates that NK cell percentages can be
used as an (in)activity biomarker [29].
NK cell proportions correlate with duration of remission
NK cell proportions correlated with the duration of re-
mission (n = 28, r = 0.74, p < 0.0001) (Fig. 3a). Likewise,
absolute NK cell counts correlated with the duration of
remission (n = 11, r = 0.69, p = 0.0198) (data not shown).
Principally, shifting of lymphocyte populations might
be caused by medication. To further address the possible
impact of disease stage and therapy, patients with in-
active GPA were divided into two groups according to
the median duration of remission (4.08 years) (Fig. 3b).
Kruskal-Wallis analysis revealed significantly different
NK cell proportions between patients with active GPA,
patients with shorter remission, and patients with longer
remission (Fig. 3b).
During clinical remission, maintenance therapy is
usually tapered gradually. In our patient cohort, all
patients with shorter remission (n = 8/8) received con-
tinued DMARD therapy (Fig. 3c, d). However, only
44 % of patients with longer remission (n = 4/9) re-
ceived continued DMARD therapy. No different NK
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cell proportions were detectable after subgrouping ac-
cording to DMARD type (Fig. 3c, d). Therefore, in-
creased NK cell proportions were associated with
both long-term remission and tapered maintenance
therapy.
B-cell depletion by rituximab might increase
remaining lymphocyte proportions. However, rituximab
was infused in a minority of our patients (n = 5/28). The
statistically significant difference between NK cell pro-
portions from patients with active GPA and those with
A
B
Fig. 1 CD56+ cells are not detectable in granulomatosis with polyangiitis (GPA) but are present in granulomas of classical granulomatous diseases.
Patient material was derived from and processed in the Heidelberg tissue bank for inflammatory diseases. Sequential paraffin-embedded sections were
stained with hematoxylin and eosin (HE) (left column), anti-CD3 antibody (middle column), and anti-CD56 antibody (right column). a Normal tonsil tissue
served as a positive control for CD3 and CD56 staining (top row). Representative tissue sections of granulomas from tuberculosis (Tb) (n = 5; second
row), sarcoidosis (n = 5; third row), and GPA (n = 13; bottom row) patients. Healthy lung tissue at the border of GPA granulomas contained scattered
CD56+ cells (not shown). Arrowheads point to giant cells. N necrosis. Measurement bars indicate 100µm. b Enlarged cutout from the sequential Tb
sections shown in (a). Upper arrows, CD3−CD56+ natural killer (NK) cells; lower arrows, CD3+CD56+ T cells
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inactive GPA remained unchanged after elimination of
these patients (not shown).
In investigating whether steroids influence NK cell
numbers, we found a statistically significant but weak
negative correlation between steroid dosage and NK
cell proportions (r = −0.43, p = 0.03) (not shown). Ster-
oid dosages in patients with active GPA were significantly
higher than in those with inactive GPA (p = 0.04). All pa-
tients with inactive GPA received either low-dose steroids
(equivalent of 5 mg of prednisone) or no steroids at all.
A B C
D E
Fig. 2 Natural killer (NK) cell proportions negatively correlate with granulomatosis with polyangiitis (GPA) activity and are increased in inactive
GPA. Peripheral blood mononuclear cells from patients and healthy controls (HCs) were isolated using Ficoll-Paque density gradient medium and
analyzed by flow cytometry. a Gating strategy. Peripheral blood lymphocytes (PBLs) were determined using forward and sideward scatter (FSC
and SSC, respectively). Cell viability was confirmed by negative 7-aminoactinomycin (7-AAD) staining in each experiment. NK cells were determined by
costaining of CD3 (negative) and CD56 (positive). b Scatterplot showing the relationship between NK cell proportions and Birmingham Vasculitis
Activity Score (BVAS). Note that in one case, two patients are represented by a single dot; both had a BVAS of 3 and NK cell proportions of 15.6 % and
15.8 %, respectively (n = 28). Spearman’s correlation coefficient (r) and statistical significance were as indicated on the figure. c and d Box-and-whisker
plots. Whiskers represent 10th–90th percentile range, statistical significance is as indicated. Left graph in (c) depicts NK cell proportions of PBLs from
HCs (n = 29), patients with active GPA (n = 11), patients with inactive GPA (n = 17), and patients with inactive systemic inflammatory control diseases
(CD; n = 12). Right graph in (c) illustrates NK cell counts in PBLs from patients with active GPA (n = 6), patients with inactive GPA (n = 5), and patients
with inactive CD (n = 12). Statistical significance was determined by Kruskal-Wallis test (p = 0.0002 for relative and p = 0.014 for absolute
NK cell numbers) and Dunn’s multiple comparison posttests (asterisks) as shown in the graphs. d T-cell proportions of patients with active
(n = 11), inactive (n = 17) GPA and of HCs. Statistical analysis using the Kruskal-Wallis test revealed that CD56− but not CD56+ T-cell proportions were
significantly different (p = 0.04). Dunn’s multiple comparison posttests were positive where indicated by asterisks. e Receiver operating characteristic
curve showing sensitivity and specificity of different NK cell proportions to distinguish inactive from active GPA. NK cells >18.5 % of PBLs determined
GPA inactivity with a specificity of 100 % and a sensitivity of 71 %. AUC area under the curve
Merkt et al. Arthritis Research & Therapy  (2015) 17:337 Page 6 of 11
Steroid dosages in inactive CD were similar to
inactive GPA and equally significantly lower than in
active GPA (p = 0.01).
Thus, we conclude that NK cell proportions correlate
with duration of remission. The highest NK cell propor-
tions were found in patients with long-term remission
and tapered maintenance therapy. Rituximab, DMARDs,
and (withdrawal of ) steroids do not contribute to this
increase in NK cells.
The majority of peripheral blood NK cells in GPA and HC
are mature CD56dim NK cells
Concordant with the literature, most HC peripheral
blood NK cells in our study corresponded to the
CD56dim subset (Fig. 4a). This was unchanged in sam-
ples of patients with GPA (Fig. 4a). The NK cell subset
distribution was similar between active and inactive
GPA (not shown).
NK cells from patients with GPA and HCs degranu-
lated to a comparable degree in the presence of target
cells from an epithelial or lymphatic origin (Fig. 4b, c).
To further investigate general NK cell functionality,
we selected as an example the NK cell p30-related pro-
tein (NKp30) pathway. NKp30 is an important activating
NK cell receptor with a known ligand, B7-H6. In the HC
group, a median of 94 % of NK cells expressed NKp30
(Fig. 5a). This was unchanged in GPA (median 95 %).
The percentage of NKp30+ NK cells was not different
between active and inactive GPA (not shown). Surface
overexpression of NKp30 ligand B7-H6 on target cells
(Fig. 5d) significantly increased the degranulation of
both HC (not shown) and GPA NK cells (Fig. 5b, c).
Finally, the proportion of NKp46+ NK cells in HC and
GPA was identical (not shown). Almost all NK cells
from HC and patients with GPA expressed NK group 2,
member D (NKG2D; not shown).
These data demonstrate that NK cells in GPA are ma-
ture cells with preserved competence for target cell
recognition.
Discussion
Principally, NK cells could both promote and limit auto-
immune inflammation [23, 30–32]. Tognarelli et al. im-
plicated NK cells in the pathogenesis of GPA for the
first time [16]. However, the presence of NK cells in
GPA tissue lesions has not yet been investigated, and
blood NK cells have not yet been correlated to disease
activity. Correlation to disease activity is a pivotal step
toward increasing understanding of the function of NK
cells in systemic inflammatory diseases [30].
The first major result of our study is that CD56+ cells
were not detectable in GPA granulomas, but in granu-
lomas from sarcoidosis and tuberculosis. The interpret-
ation of this finding is somewhat limited, as CD56 is not
specific for NK cells; it is also expressed by T-cell sub-
sets. However, our failure to detect CD56+ cells suggests
that potentially pathogenic [16] NK cells are not present
in GPA granulomas. We conclude that NK cells are un-
likely to contribute to GPA granuloma formation or,
alternatively, that they disappear during granuloma
A B C D
Fig. 3 Natural killer (NK) cell proportions correlate with duration of remission. NK cell proportions of peripheral blood lymphocytes (PBLs) were
determined by flow cytometry as described in Fig. 2. a Scatterplot showing the relationship between NK cell proportion and the duration of
remission (in years). Spearman’s correlation coefficient (r) and statistical significance are as indicated above the graph. b Box-and-whisker plot
showing NK cell proportions of inactive patients with GPA with <4.08 years of remission (n = 8) and ≥4.08 years of remission (n = 9). Statistical
significance was determined by Kruskal-Wallis test (p = 0.0003) and Dunn’s multiple comparisons posttests (asterisks indicate statistical significance).
c Reconfiguration of scatterplot shown in (b) after subgrouping according to disease-modifying antirheumatic drug (DMARD) therapy. d Overview of
immunosuppressive maintenance/DMARD therapy. Left column, patients with <4.08 years of remission. Right column, patients with ≥4.08 years of
remission. Each row of each column represents a single patient
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development. In any case, a potential pathogenic role of
NK cells (e.g., by killing endothelial cells, as suggested
by Tognarelli et al. [16]) in renal vasculitis whereby NK
cells might also act via the luminal vessel side cannot be
excluded. Beyond that, the different expression pattern
of CD56 constitutes a clear difference between GPA
granulomas and granulomas of classical granulomatous
diseases such as tuberculosis and sarcoidosis. This differ-
ent pattern has not been described before and might have
an impact on granulomatous inflammation research aside
from GPA. The numerous CD56+ cells in tuberculosis and
sarcoidosis are most presumably a mixture of NK cells
A B C
Fig. 4 Natural killer (NK) cells in granulomatosis with polyangiitis (GPA) are mature cells with preserved competence for immune recognition. Peripheral
blood mononuclear cells (PBMCs) were isolated and analyzed by flow cytometry as described in Fig. 2. a Dot blots showing the percentages of CD56dim
NK cells from healthy control subjects (HCs; n = 29) and patients with GPA (n = 28). b, c Bar graphs showing the additive effect on degranulation of NK
cells after 4-h incubation of PBMCs with target cell lines. For further details of the experimental setup, see Material and methods section. b The additive
effect on degranulation of NK cells from patients with GPA (n = 5; 2 active, 3 inactive) and HCs (n = 7) cultured with the epithelial cell line
BxPC-3 transfected with a vector control (BxPC3-VC). c The additive effect on degranulation of NK cells from patients with GPA (n = 2; 1
active, 1 inactive) and HCs (n = 3) cultured with the JE6-1 (leukemic Jurkat) lymphatic cell line transfected with a vector control (JE6-1-VC).
The additive effect on degranulation is defined by the percentage NK cells expressing the degranulation marker CD107a after incubation
with target cells minus the percentage of NK cells expressing the degranulation marker CD107a after incubation without target cells. Statistical analysis
was performed using the Mann-Whitney U test (not significant)
A B C D
Fig. 5 Natural killer (NK) cells from patients with granulomatosis with polyangiitis (GPA) can be activated via the NK cell p30-related protein (NKp30)
pathway. Peripheral blood mononuclear cells (PBMCs) were isolated and analyzed by flow cytometry as described in Fig. 2. a Dot blots showing the
percentages of NKp30+ NK cells from healthy control subjects (HCs; n = 29) and patients with GPA (n = 28). b and c Bar graphs depicting the
additive effect on degranulation of NK cells after 4-h incubation of PBMCs of patients with GPA with target cell lines. The additive effect on
degranulation of NK cells from PBMCs cultured with the vector controls (VCs) shown in Fig. 4b and c is contrasted with the additive effect on
degranulation after incubation with (b) BxPC-3 (n = 5; 2 active, 3 inactive) and (c) JE6-1 (n = 2; 1 active, 1 inactive) overexpressing NKp30
ligand B7-H6, respectively. The additive effect on degranulation is defined by the percentage of NK cells expressing the degranulation
marker CD107a after incubation with target cells minus the percentage of NK cells expressing the degranulation marker CD107a after incuba-
tion without target cells. *Statistical significance was determined using a paired t test. d Representative histogram showing the surface expression of B7-H6
on BxPC-3 transduced with B7-H6 or the VC. B7-H6 expression on transduced JE6-1 was comparable to that on BxPC-3. IgG1 immunoglobulin G1
isotype control
Merkt et al. Arthritis Research & Therapy  (2015) 17:337 Page 8 of 11
and CD56+ T-cells (Fig. 1b). Concordantly, other groups
have reported that NK cells can be found in granulomas,
such as in tuberculosis [33, 34]. Of note, Moins-
Teisserenc et al. described a syndrome resembling
therapy-refractory GPA with strong tissue infiltration by
NK cells [35].
The reasons for a local NK cell deficiency in GPA
granulomas are unclear, but they might include the spe-
cific inflammatory environment or chemotaxis. As NK
cells were not detectable in active granulomatous GPA
lesions, a disease- or at least a granuloma-promoting
role of NK cells seems unlikely.
The second major finding of this study is the increase
of peripheral blood NK cell proportions in inactive GPA.
This finding is underlined by the negative correlation to
BVAS and the positive correlation to the duration of re-
mission. Importantly, this was not seen in our inactive
CD cohort. As there is no perfect CD for GPA, we used
a mixture of other systemic inflammatory diseases. In
the literature, the authors of most studies of autoimmune
diseases (systemic lupus erythematosus, rheumatoid
arthritis, Sjögren’s syndrome, and others) have reported
decreased NK cells in peripheral blood [30]. To our know-
ledge, no study to date has shown an increase of NK cells
above normal HC levels in rheumatologic patients in re-
mission, as we describe here in GPA. The NK cell increase
therefore seems characteristic for GPA.
Interestingly, a rare hematologic disease with
chronic NK cell lymphocytosis [lymphoproliferative
disease of large granular lymphocytes (LDGL)] is as-
sociated with autoimmune syndromes, including arth-
ritis and vasculitis. NK cell lymphocytosis in these
patients results from an aberrant expansion of an im-
mature and functionally deficient NK cell population
[32]. Therefore, in the third part of this study, we fur-
ther characterized NK cells in GPA in relation to its
activity. In contrast to NK cells in LDGL, NK cells in
inactive GPA appeared to be normal mature NK cells.
This is suggested by a normal subset distribution ac-
cording to the expression levels of CD56, by the
equipment with functional NK cell receptors, and by
a normal response to target cells, including preserved
discrimination between targets overexpressing specific
NK cell receptor ligands. We therefore conclude that
NK cells in both active and inactive GPA are nor-
mally immune-competent. We found no signs of hy-
poresponsiveness as are seen in several rheumatologic
diseases [30]. Tognarelli et al. reported elevated sur-
face expression of CD107a on NK cells from patients
with GPA as an indirect sign of in vivo activation.
Regardless of this, we did not find increased surface
expression of CD107a on GPA compared with HC
NK cells in our degranulation assay negative controls
without activation by target cells (not shown).
Possible reasons for increased NK cell proportions
might include changes in NK cell maturation, develop-
ment, proliferation, or survival. In a large study of 137
patients with GPA, researchers found elevated inflam-
matory serum proteins in active GPA and a significant
reduction of many but not all of those markers during
the disease course [36]. Therefore, a disturbed regulation
of NK cells by cytokines and chemokines could play a
central role in explaining altered NK cell levels. Interest-
ingly, elevated blood levels of IL-15 and IL-18 were re-
ported in both active and inactive GPA [36]. IL-15 and
IL-18 have crucial roles in NK cell homeostasis [37, 38].
On the basis of recently published data, a disturbed con-
trol of NK cells by regulatory T cells needs to be consid-
ered [39–41]. In inactive GPA, proportions of regulatory
T cells are increased but reportedly functionally deficient
[42]. Alternatively, increased blood proportions could be
affiliated with a different migration of NK cells. A single
study showed an upregulation of chemokine (C-C motif )
receptor type 5 on NK cells in active GPA [43]. To-
gether, these studies [36, 42, 43] render the NK cell
increase in inactive GPA feasible.
Different immunosuppressive regimen and steroid
dosages might also shift lymphocyte proportions. On
one hand, patients with active GPA usually receive
stronger induction therapy, which was associated with
lower NK cell counts in our study. On the other hand,
we saw increasing NK cell proportions in three of four
patients who were followed during (re)induction therapy
(data not shown), indicating an increasing effect of
strong immunosuppression on NK cell percentages. The
less potent maintenance therapy in inactive GPA was in-
directly associated with elevated NK cell counts, but
long-term remission was associated with less mainten-
ance therapy and even more NK cells. Concerning ster-
oid dosages, patients with inactive GPA received steroid
dosages similar to those of patients with inactive CD
without elevation of NK cell proportions. Furthermore,
despite significantly lower steroid dosages in inactive CD
compared with active GPA, NK cell proportions did not
differ between these groups. As these contradictory ob-
servations exclude a clear increasing or decreasing effect
of immunosuppression on NK cell proportions, a direct
effect is unlikely. In summary, elevation of NK cell pro-
portions is a correlate of clinical amelioration and not of
alterations of medication.
A permanent challenge in treating GPA is to interpret
new and unspecific complaints of a patient in remission,
such as fever or night sweats, that could also be unre-
lated to GPA. To date, biomarkers of disease activity that
can reliably confirm or exclude GPA activity are missing.
The availability of such biomarkers could objectify treat-
ment decisions that are to date based largely on the phy-
sician’s experience. Therefore, all recent reviews on this
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topic emphasize the importance of the identification of
new biomarkers in GPA [8, 29, 44, 45].
In the present study, NK cell proportions in PBL
>18.5 % determined GPA inactivity with a specificity of
100 % and a sensitivity of 71 %. Importantly, the positive
likelihood ratio was >8, indicating that NK cell propor-
tions might be a useful activity biomarker [29]. Future
prospective studies with larger patient cohorts should be
done to confirm our data and tighten a suitable threshold
of normal and elevated (possibly protective) NK cell pro-
portions. Accordingly, in routine clinical practice, elevated
NK cell proportions might help to exclude GPA activity.
A better understanding of GPA pathogenesis is needed
to design new, target-specific therapies. Together with the
results reported by Tognarelli et al. (tissue origin–
dependent endothelial alteration by cytokines and killing
by NK cells) [16], our third finding suggests that abnor-
mally high killing of renal MECs by NK cells is more a re-
sult of changed endothelial cells than of altered GPA NK
cells, as the latter do not degranulate differently from HC
NK cells in the presence of target cells from epithelial,
lymphatic, and non-renal endothelial origins [21].
It would therefore be tempting to speculate that a po-
tential involvement of NK cells in GPA pathogenesis is
determined not by NK cell functionality but by the ex-
pression of NK ligands in inflamed tissues. The expres-
sion of NK cell ligands has been shown in different
inflamed GPA tissues, including granulomas [14, 15]; in
the present study, we show that GPA NK cells can
recognize ligand-bearing target cells from origins other
than the endothelium (Fig. 4).
Importantly, Holmén et al. reported that circulating
inflammatory endothelial cells express major histocom-
patibility complex class I polypeptide-related sequence
A(MIC-A), a ligand for NKG2D, and are pathogenic in
GPA [46]. These cells positively correlated with disease
activity [46]. As Tognarelli et al. showed that inflamma-
tory endothelial cells can be killed by NK cells, and as
we show a negative correlation of NK cells with disease
activity, one could speculate that NK cells can clear the
circulation from pathogenic inflammatory endothelial
cells and thus have a protective role in GPA. Beyond
that, NK cells might possess a regulatory function by
controlling other immune cells (e.g., activated CD4+
T-cells) [25].
To date, the mechanisms underlying increased blood
NK cell proportions in inactive GPA and their possible
pathophysiological role in vivo remain unknown and
should be investigated in future studies.
Conclusions
Our study increases knowledge about tissue and blood
distribution of NK cells in GPA. NK cells are not detect-
able in GPA granulomas. High NK cell percentages in
peripheral blood are associated with clinical suppression
of disease activity and might possibly be used as a bio-
marker to exclude GPA activity.
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